LSL Pharma Group Inc. (LSL.V)
| Previous close | 0.5100 |
| Open | 0.5100 |
| Bid | 0.5000 x N/A |
| Ask | 0.5100 x N/A |
| Day's range | 0.5100 - 0.5100 |
| 52-week range | 0.3500 - 0.5500 |
| Volume | |
| Avg. volume | 34,303 |
| Market cap | 55.083M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
LSL Pharma Group Reports Record Revenues and Margins for the First Quarter 2024
Record Revenues of $4.2 million in Q1-24 up 106% over Q1-23Record Adjusted Gross margins for Q1-24 of $1.6 million up 141% over Q1-23Operating profits of $0.2 million for Q1-24 compared to a loss of $0.3 million for Q1-23$0.65 million Adjusted EBITDA profit for Q1-24, up $0.65 million over Q1-232 non-brokered private placements completed for $10.1 millionBinding agreement signed to acquire a Quebec-based competing CDMOListing of Convertible debentures on TSXV under the symbol “LSL.DB” BOUCHERVIL
- GlobeNewswire
LSL Pharma Group Announces Listing of Convertible Redeemable Debentures on the TSXV
BOUCHERVILLE, Quebec, May 22, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL) (the "Corporation" or "LSL Pharma "), a Canadian integrated pharmaceutical company, is pleased to announce that the Convertible Unsecured Redeemable Debentures (the "Debentures") issued pursuant to a $3.288 million brokered private placement completed in tranches on November 1, 2023 and December 8, 2023 have been approved for listing on the TSXV under the symbol “LSL.DB” and will begin trading on May 24, 202
- GlobeNewswire
LSL Pharma Group Enters Into Binding Agreement to Acquire Quebec Competitor
Transaction expected to increase annual revenues by 15-20%Acquisition to boost overall profitabilityTransaction expected to close by end of Q2-24 BOUCHERVILLE, Québec, May 06, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC. (TSXV: LSL) ("the Company" or "LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to announce that it has entered into a binding Letter of Intent ("LOI") to acquire profitable privately held, Quebec-based competing contract drug manufacturer ("CDMO") specia
